INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 132 filers reported holding INTRA CELLULAR THERAPIES INC in Q4 2016. The put-call ratio across all filers is 0.63 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2022 | $9 | -99.1% | 180 | -94.0% | 0.00% | – |
Q3 2022 | $1,000 | -95.7% | 3,000 | -36.2% | 0.00% | -100.0% |
Q2 2022 | $23,000 | -86.3% | 4,700 | -59.8% | 0.00% | -77.8% |
Q1 2022 | $168,000 | -71.7% | 11,686 | -35.7% | 0.01% | -64.0% |
Q4 2021 | $594,000 | +1112.2% | 18,186 | +439.2% | 0.02% | +1150.0% |
Q3 2021 | $49,000 | +4.3% | 3,373 | -71.9% | 0.00% | 0.0% |
Q2 2021 | $47,000 | -31.9% | 12,000 | +194.1% | 0.00% | -33.3% |
Q1 2021 | $69,000 | -37.8% | 4,080 | -56.5% | 0.00% | -50.0% |
Q4 2020 | $111,000 | -45.0% | 9,380 | -50.1% | 0.01% | -53.8% |
Q3 2020 | $202,000 | +32.0% | 18,800 | +13.3% | 0.01% | +30.0% |
Q2 2020 | $153,000 | +125.0% | 16,600 | +155.4% | 0.01% | +233.3% |
Q1 2020 | $68,000 | -83.8% | 6,500 | -93.9% | 0.00% | -88.5% |
Q4 2019 | $420,000 | +438.5% | 107,000 | +46.2% | 0.03% | +271.4% |
Q3 2019 | $78,000 | +290.0% | 73,200 | +803.7% | 0.01% | +250.0% |
Q2 2019 | $20,000 | -54.5% | 8,100 | +42.1% | 0.00% | -50.0% |
Q1 2019 | $44,000 | -66.9% | 5,700 | -92.1% | 0.00% | -66.7% |
Q4 2018 | $133,000 | -39.5% | 72,500 | +39.4% | 0.01% | -20.0% |
Q3 2018 | $220,000 | -16.3% | 52,000 | -10.0% | 0.02% | -28.6% |
Q2 2018 | $263,000 | -27.3% | 57,749 | +2.9% | 0.02% | -32.3% |
Q1 2018 | $362,000 | +109.2% | 56,099 | +6.1% | 0.03% | +342.9% |
Q4 2017 | $173,000 | -78.5% | 52,861 | -67.6% | 0.01% | -77.4% |
Q3 2017 | $803,000 | +196.3% | 163,060 | +107.6% | 0.03% | +244.4% |
Q2 2017 | $271,000 | -58.8% | 78,544 | -56.7% | 0.01% | -67.9% |
Q1 2017 | $658,000 | +23.2% | 181,376 | +175.0% | 0.03% | +47.4% |
Q4 2016 | $534,000 | -18.1% | 65,945 | -70.7% | 0.02% | -34.5% |
Q3 2016 | $652,000 | +5.0% | 225,379 | +94.3% | 0.03% | -9.4% |
Q2 2016 | $621,000 | +11.9% | 115,981 | +94.3% | 0.03% | -11.1% |
Q1 2016 | $555,000 | +173.4% | 59,702 | +161.0% | 0.04% | +227.3% |
Q4 2015 | $203,000 | – | 22,874 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |